Abstract
Onychomycosis is the most common nail disease and describes the invasion of the nail by fungi. In most cases, treatment of onychomycosis requires systemic antifungals, with duration of administration ranging from 2 to several months. Cure rates range from 60% to 80%, and relapses are not rare (up to 20% of patients). New antifungals providing higher cure rates and less relapses are, therefore, auspicable. A review of onychomycoses and their treatment is made and the new antifungal drugs that are currently on study or already available are presented.
| Original language | English |
|---|---|
| Pages (from-to) | 155-159 |
| Number of pages | 5 |
| Journal | Giornale Italiano di Dermatologia e Venereologia |
| Volume | 141 |
| Issue number | 2 |
| State | Published - Jan 1 2006 |
| Externally published | Yes |
Fingerprint
Keywords
- Antimicotics
- Nails
- Posaconazole
- Ravuconazole
- Voriconazole
ASJC Scopus subject areas
- Dermatology
Cite this
Emerging agents for onychomycosis. / Piraccini, B. M.; Iorizzo, M.; Rech, G.; Tosti, Antonella.
In: Giornale Italiano di Dermatologia e Venereologia, Vol. 141, No. 2, 01.01.2006, p. 155-159.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Emerging agents for onychomycosis
AU - Piraccini, B. M.
AU - Iorizzo, M.
AU - Rech, G.
AU - Tosti, Antonella
PY - 2006/1/1
Y1 - 2006/1/1
N2 - Onychomycosis is the most common nail disease and describes the invasion of the nail by fungi. In most cases, treatment of onychomycosis requires systemic antifungals, with duration of administration ranging from 2 to several months. Cure rates range from 60% to 80%, and relapses are not rare (up to 20% of patients). New antifungals providing higher cure rates and less relapses are, therefore, auspicable. A review of onychomycoses and their treatment is made and the new antifungal drugs that are currently on study or already available are presented.
AB - Onychomycosis is the most common nail disease and describes the invasion of the nail by fungi. In most cases, treatment of onychomycosis requires systemic antifungals, with duration of administration ranging from 2 to several months. Cure rates range from 60% to 80%, and relapses are not rare (up to 20% of patients). New antifungals providing higher cure rates and less relapses are, therefore, auspicable. A review of onychomycoses and their treatment is made and the new antifungal drugs that are currently on study or already available are presented.
KW - Antimicotics
KW - Nails
KW - Posaconazole
KW - Ravuconazole
KW - Voriconazole
UR - http://www.scopus.com/inward/record.url?scp=33646834300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646834300&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33646834300
VL - 141
SP - 155
EP - 159
JO - Giornale Italiano di Dermatologia e Venereologia
JF - Giornale Italiano di Dermatologia e Venereologia
SN - 0392-0488
IS - 2
ER -